5-methoxynicotinohydrazide | 89853-73-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-methoxynicotinohydrazide
• 英文别名: 5-Methoxy-nicotinsaeure-hydrazid；5-Methoxynicotinohydrazide；5-methoxypyridine-3-carbohydrazide
• CAS: 89853-73-6
• 化学式: C₇H₉N₃O₂
• mdl: MFCD18803355
• 分子量: 167.167
• InChiKey: XCVXJIVZDYBHGB-UHFFFAOYSA-N

物化性质

• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  77.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-bromo-3-chloro-2-methylquinoxaline 、 5-methoxynicotinohydrazide 在 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl 、 palladium diacetate 、 caesium carbonate 作用下， 以 四氢呋喃 、 水 、 正丁醇 为溶剂， 反应 2.0h， 生成 1-(5-methoxypyridin-3-yl)-4-methyl-8-(morpholin-4-ylmethyl)[1,2,4]triazolo[4,3-a]quinoxaline
  参考文献：
  名称：

  Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement

  摘要：

  Structure-guided design led to the identification of the novel, potent, and selective phosphodiesterase 2 (PDE2) inhibitor 12. Compound 12 demonstrated a >210-fold selectivity versus PDE10 and PDE11 and was inactive against all other PDE family members up to 10 mu M. In vivo evaluation of 12 provided evidence that it is able to engage the target and to increase cGMP levels in relevant brain regions. Hence, 12 is a valuable tool compound for the better understanding of the role of PDE2 in cognitive impairment and other central nervous system related disorders.

  DOI：

  10.1021/ml500262u
• 作为产物：
  描述：

  5-甲氧基吡啶-3-羧酸甲酯 在 hydrazine hydrate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 5-methoxynicotinohydrazide
  参考文献：
  名称：

  Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement

  摘要：

  Structure-guided design led to the identification of the novel, potent, and selective phosphodiesterase 2 (PDE2) inhibitor 12. Compound 12 demonstrated a >210-fold selectivity versus PDE10 and PDE11 and was inactive against all other PDE family members up to 10 mu M. In vivo evaluation of 12 provided evidence that it is able to engage the target and to increase cGMP levels in relevant brain regions. Hence, 12 is a valuable tool compound for the better understanding of the role of PDE2 in cognitive impairment and other central nervous system related disorders.

  DOI：

  10.1021/ml500262u

文献信息

• [EN] TRIAZOLE AGONISTS OF THE APJ RECEPTOR<br/>[FR] TRIAZOLES AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2016187308A1

  公开（公告）日：2016-11-24

  Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药用盐，上述任何一种的立体异构体，或它们的混合物是APJ受体的激动剂，并可用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构，其中变量的定义在此提供。
• Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors
  作者：José-Ignacio Andrés、Peter Buijnsters、Meri De Angelis、Xavier Langlois、Frederik Rombouts、Andrés A. Trabanco、Greet Vanhoof

  DOI：10.1016/j.bmcl.2012.11.077

  日期：2013.2

  The synthesis, preliminary evaluation and structure–activity relationship (SAR) of a series of 1-aryl-4-methyl[1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors are described. From this investigation compound 31 was identified, showing good combined potency, acceptable brain uptake and high selectivity for both PDE2 and PDE10 enzymes. Compound

  一系列1-芳基-4-甲基[1,2,4]三唑并[4,3- a ]喹喔啉作为双磷酸二酯酶2 /磷酸二酯酶10（PDE2 /描述了PDE10）抑制剂。从该研究中鉴定出化合物31，对PDE2和PDE10酶均显示出良好的综合效价，可接受的大脑摄取和高选择性。化合物31在大鼠中进行了微剂量实验，显示了在PDE2和PDE10均高表达的大脑区域中的优先分布。这些有希望的结果可能会推动高效联合PDE2 / PDE10抑制剂，甚至PDE2和/或PDE10选择性抑制剂的进一步开发。
• TRIAZOLE AGONISTS OF THE APJ RECEPTOR
  申请人：AMGEN INC.

  公开号：US20170044131A1

  公开（公告）日：2017-02-16

  Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药用可接受的盐，任何上述的立体异构体，或其混合物均为APJ受体激动剂，并可用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构：其中变量的定义在此处提供。
• METHODS OF TREATING HEART FAILURE
  申请人：AMGEN INC.

  公开号：US20170281625A1

  公开（公告）日：2017-10-05

  Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.

  治疗心力衰竭的方法包括向患有心力衰竭的受试者投予一种有效量的三唑化合物，该化合物是APJ受体的激动剂，或其药学上可接受的盐，或两者的混合物。本文提供了特别适用于此类方法的化合物。
• BROMOTRIAZOLE INTERMEDIATES
  申请人：AMGEN INC.

  公开号：US20190100510A1

  公开（公告）日：2019-04-04

  Bromotriazole intermediates are useful in the synthesis of agonists of the APH receptor. Such compounds include those selected from

  溴三唑中间体在合成APH受体激动剂方面非常有用。这些化合物包括从中选择的化合物。